Glenmark gains favourable arbitration ruling in crofelemer case with Napo
This article was originally published in Scrip
Executive Summary
An international arbitrator has ruled in favour of Glenmark Pharmaceuticals upholding, among others, the Indian firm's commercialisation rights to Napo Pharmaceuticals' anti-secretory gastrointestinal agent, crofelemer